Archives
-
GPC3-HSP70 mRNA Nanovaccine for HCC
2026-09-12
The reference study develops an mRNA nanovaccine encoding tandem GPC3 CTL epitopes fused to HSP70 and delivered through an SP94-based cationic peptide system. In preclinical experiments, vaccination increased antigen-specific T-cell activity, while combination with anti-PD-L1 therapy produced stronger antitumor responses than either strategy alone.
-
Sulfo-NHS-SS-Biotin for Reversible Protein Labeling
2026-09-11
Sulfo-NHS-SS-Biotin combines aqueous amine reactivity with a reducible disulfide spacer, enabling cell-surface labeling, reversible capture, and controlled protein purification. This workflow also provides a practical orthogonal assay for studying trafficking-deficient proteins alongside the IRE1/XBP1s findings reported for GABAA receptor variants.
-
EZ Cap EGFP mRNA 5-moUTP Workflows
2026-09-11
Turn a fluorescent mRNA transcript into a quantitative tool for separating delivery, intracellular release, translation, and cell health. This workflow combines the defined properties of EZ Cap™ EGFP mRNA (5-moUTP) with practical controls inspired by redox-responsive peptide coacervate research.
-
mCherry mRNA: From Reporter to Delivery Readout
2026-09-10
Learn how mCherry mRNA can function not only as a red fluorescent reporter but also as a practical measurement tool for evaluating nanoparticle loading, intracellular delivery, and translation. This guide connects Cap 1 design and modified nucleotides with kidney-targeted mRNA formulation decisions.
-
TRAP-1 Activates Mutant p53Y220C
2026-09-10
The bioRxiv preprint identifies TRAP-1, a small-molecule inducer of proximity that assembles mutant p53Y220C and BRD4 into a ternary complex, restoring transcriptional activity in cellular models. Its genetic and pharmacological controls support chemically induced proximity as the key mechanism, while the preclinical design leaves questions about selectivity, safety, and activity beyond p53Y220C-expressing cell lines.
-
HA-LNP PTEN mRNA for Transdermal Melanoma Therapy
2026-09-09
The reference study develops hyaluronate-conjugated lipid nanoparticles containing HA-DMG to deliver PTEN mRNA through skin and into melanoma tissue. Its findings connect localized PTEN restoration with reduced tumor growth, immunogenic cell death, and enhanced antitumor immune activation, while also identifying important translational limits for future cancer research.
-
Ethacridine Lactate Monohydrate in Assay Design
2026-09-09
Ethacridine lactate monohydrate can support microbial control in sensitive biochemical and cell-based workflows, but its value depends on disciplined compatibility testing. This article connects its product specifications with the YAP–TEAD super-enhancer study to define practical controls, interpretation boundaries, and research-use decisions.
-
YAP-TEAD Control of Surface Ectoderm Super-Enhancers
2026-09-08
Wang et al. map how super-enhancers and three-dimensional chromatin contacts coordinate early surface ectoderm commitment from pluripotent stem cells. Their perturbation experiments identify YAP-TEAD activity, particularly TEAD-dependent regulation, as a functional driver of enhancer establishment, target-gene activation, and epithelial lineage progression.
-
Spermine Tetrahydrochloride: From Charge to Translation
2026-09-08
Spermine tetrahydrochloride is more than a polyamine reagent: its charge-driven behavior links membrane protection, protein crystallization, and polyphosphazene nanoparticle engineering. This translational perspective shows how to use the chemistry without overstating the evidence.
-
MK-4827: Mapping PARP Inhibitor Resistance
2026-09-07
MK-4827 (Niraparib) offers a precise way to study PARP-dependent DNA damage repair and resistance after platinum exposure. This article translates recent ovarian cancer findings into a sequence-aware assay strategy for BRCA-mutant, resistant, and combination-treatment models.
-
Henagliflozin and Aging Biomarkers in Type 2 Diabetes
2026-09-07
A 2025 multicenter randomized trial found that 26 weeks of henagliflozin improved telomere length, glucose metabolism, insulin-like growth factor signaling, immune-cell markers, and selected metabolites in adults with type 2 diabetes. The findings support a multitarget biomarker hypothesis for SGLT2 inhibitor effects while remaining distinct from proof of clinical anti-aging benefit.
-
Modeling Breast Cancer Relapse with Proliferation Tracing
2026-09-05
The referenced npj Breast Cancer study introduces a dual recombinase system that traces and ablates recently proliferating cells in spontaneous MMTV-PyMT mammary tumors. Its single-cell analysis shows that relapse is associated with low-cycling tumor reservoirs, increased cancer stem-cell features, protumor γδ T cells, and coordinated Spp1–Vegfa expression in myeloid populations, providing a model for testing relapse-focused therapies.
-
Kidney-Targeted mRNA Nanoparticles: Study Insights
2026-09-04
The 2024 Pace University dissertation examined how excipients alter mRNA loading in a polymeric mesoscale nanoparticle platform designed for kidney-directed delivery. Its comparison of DOTAP, trehalose, and calcium acetate links formulation chemistry with encapsulation, particle quality, cellular uptake, cytotoxicity, pharmacokinetics, and protein-expression readouts.
-
HBsAg, TBK1, and Early Autophagy in HBV
2026-09-04
The reference study identifies a mechanism in which hepatitis B surface antigen redirects TBK1 signaling away from IRF3 and toward p62-associated autophagy. By linking impaired type I interferon signaling with incomplete autophagic flux, the work explains how HBsAg may support HBV persistence and provides a framework for studying immunity–autophagy crosstalk.
-
EZ Cap EGFP mRNA 5-moUTP: Assay Workflows
2026-09-03
Learn how to use EZ Cap EGFP mRNA 5-moUTP as a reproducible fluorescent reporter for delivery, translation, viability, and imaging studies. The workflow connects Cap1, 5-moUTP, and poly(A) design with practical controls inspired by recent extracellular-vesicle mRNA delivery research.